Results 161 to 170 of about 10,355,590 (280)

Cell-Free DNA and Mitochondria in Parkinson's Disease. [PDF]

Int J Mol Sci
Wojtkowska M, Ambrosius F.
europepmc   +1 more source

Spatial biology in cancer epigenetics

Molecular Oncology, EarlyView.
Spatial epigenomics combines molecular profiling with tissue architecture to reveal how gene regulation is organized within intact tissues. In cancer, these technologies uncover the mechanisms driving tumor heterogeneity and microenvironmental interactions, opening new opportunities for biomarker discovery and precision medicine.
Eva Crespo‐García, Manel Esteller
wiley   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Identification of a G-quadruplex-forming cell-free DNA fragment as a biomarker for the precise diagnosis of hepatocellular carcinoma. [PDF]

Chem Sci
Sun J, Teng X, Zhang W, Dai Y, Liu L, Li J.   +5 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Early detection of gastric cancer with the assistance of cell-free DNA fragmentomics. [PDF]

Clin Epigenetics
Huang X, Han Z, Zhang Y, Wang H, Li X, Bai C, Pan Y, Huang J, Xie J, Qian X, Wang X, Ding T, Zhang J, Yang S, Hong X, Jing Q, Li G, Li X.   +17 more
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

Diagnostic Testing After Positive Cell-Free DNA Screening for Sex Chromosome Aneuploidies: Clinical and Socioeconomic Determinants. [PDF]

Prenat Diagn
Stevens BK, Araji S, Maktabi MA, Liu R, Westerfield L, Wassef M, Lai D, Van den Veyver IB, Krishnan M, Lawrence C, Prakash SK.   +10 more
europepmc   +1 more source

Castration‐resistant prostate cancer cells are addicted to the high activity of cyclin‐dependent kinase 2

Molecular Oncology, EarlyView.
We show that emergence of castration‐resistant prostate (CRPC) is associated with significant upregulation of cyclins that positively regulate cyclin‐dependent kinase 2 (CDK2) and concomitant downregulation of CDK4 cyclins. This renders CRPC cells dependent on the high activity of CDK2, and CDK2 inhibitors synergistically sensitize CRPC cells to both ...
Joyeeta Chatterjee, Alessia Marin, Shivani Yalala, Harri M. Itkonen   +3 more
wiley   +1 more source

Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma. [PDF]

Cell Rep Med
Wang S, Mapar P, Moldovan N, van der Pol Y, Safrastyan A, van Werkhoven E, Tantyo NA, Snieder B, Do Brito Valente AF, de Jonge AV, Dinmohamed A, Drees EEE, Roemer MGM, Ylstra B, Klerk CPW, Strobbe L, Sandberg Y, Boersma RS, Koene H, Pruijt H, de Heer K, van Rijn R, Bilgin YM, de Jongh E, Nijland M, van der Poel M, Koster A, Nieuwenhuizen L, Fijnheer R, Beeker A, Mous R, Vergote VKJ, Vermaat JSP, Pegtel DM, Chamuleau MED, Mouliere F.   +35 more
europepmc   +1 more source